Biogen and Eisai Stop Phase 3 Trials of Aducanumab in Alzheimer's Disease
March 22, 2019
March 22, 2019
CHICAGO, Illinois, March 22 -- The Alzheimer's Association issued the following news release:
On behalf of the millions of people living with Alzheimer's disease and their families that we serve and represent, the Alzheimer's Association is disappointed to hear the report from Biogen and Eisai that an analysis conducted by an independent data monitoring committee indicated two Phase 3 trials of aducanumab were unlikely to be successful. As a result, the companies have discontinued P . . .
On behalf of the millions of people living with Alzheimer's disease and their families that we serve and represent, the Alzheimer's Association is disappointed to hear the report from Biogen and Eisai that an analysis conducted by an independent data monitoring committee indicated two Phase 3 trials of aducanumab were unlikely to be successful. As a result, the companies have discontinued P . . .